NR
NRXPW
NRX Pharmaceuticals, Inc.
No data for this timeframe.
Vol
Market Cap$139.1M
Cap SizeMicro Cap
Inst. Holders1 funds
Inst. Value$347.00
Inst. Activity0 buys / 1 sells
SEC Reports4
Recent Activity
Jun 4, 2026
SEC
NRx Pharmaceuticals closed a firm-commitment underwritten public offering of 5,714,286 shares of common stock at $3.50 p
8-K — Impact 6/10
Jun 3, 2026
SEC
NRx Pharmaceuticals is conducting a firm-commitment underwritten public offering of 5,714,286 shares of common stock at
424B5 — Impact 6/10
Jun 2, 2026
SEC
NRx Pharmaceuticals filed a preliminary prospectus supplement for an underwritten firm-commitment common stock offering
424B5 — Impact 6/10
Inst.
UBS Group AG — NEAR_EXIT
18 shares ($1.00)
Inst.
UBS Group AG — ADD
1,500 shares ($128.00)
Latest Reports
BEARISH
8-K
6/10
NRx Pharmaceuticals closed a firm-commitment underwritten public offering of 5,714,286 shares of common stock at $3.50 p
Jun 4, 2026
BEARISH
424B5
6/10
NRx Pharmaceuticals is conducting a firm-commitment underwritten public offering of 5,714,286 shares of common stock at
Jun 3, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| WOLVERINE ASSET MANAGEMENT LLC | $347.00 | DOUBLED |
1 institutional holders with $347.00 total value (23,593 shares) as of 2026-Q1. Top holders: WOLVERINE.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | WOLVERINE ASSET MANAGEMENT LLC | 23,593 | $347.00 | 100.0% | DOUBLED +290.7% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| UBS Group AG | NEAR_EXIT | 1,500 | 18 | -98.8% | $1.00 | 2025-Q3 |
| UBS Group AG | ADD | 1,032 | 1,500 | +45.3% | $128.00 | 2025-Q2 |
| WOLVERINE ASSET MANAGEMENT LLC | DOUBLED | 5,190 | 20,278 | +290.7% | $1.4K | 2025-Q1 |
| UBS Group AG | TRIM | 3,911 | 1,032 | -73.6% | $73.00 | 2025-Q1 |
| WOLVERINE ASSET MANAGEMENT LLC | TRIM | 15,392 | 5,190 | -66.3% | $664.00 | 2024-Q4 |
| UBS Group AG | TRIM | 15,251 | 3,911 | -74.4% | $501.00 | 2024-Q4 |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
4 SEC filing reports analyzed. Sentiment: 0 bullish, 4 bearish, 0 mixed, 0 neutral. Avg impact: 6.5/10.
BEARISH
8-K
6/10
NRx Pharmaceuticals closed a firm-commitment underwritten public offering of 5,714,286 shares of com
Jun 4, 2026
BEARISH
424B5
6/10
NRx Pharmaceuticals is conducting a firm-commitment underwritten public offering of 5,714,286 shares
Jun 3, 2026
BEARISH
424B5
6/10
NRx Pharmaceuticals filed a preliminary prospectus supplement for an underwritten firm-commitment co
Jun 2, 2026
BEARISH
25-NSE
8/10
Nasdaq filed a Form 25-NSE to remove from listing and deregister the warrants (NRXPW) of NRX Pharmac
May 22, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | 0.0% | — |
| Next Q 2026-09-30 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | 341.3% | — |
| Current FY 2026-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.0B | 248.7% | — |
| Next FY 2027-12-31 |
$0.00 | $0.00 | $0.00 | — | — | — | $0.3B | 6963.1% | — |
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
No events recorded for this ticker. Events include FDA actions, clinical trials, enforcement actions, and market-moving developments.